Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for ... for rights to the programme that includes a Phase II asset trialled for ulcerative colitis (UC) and metabolic dysfunction-associated ...

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $ ... is in phase I/II testing as a rescue therapy ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... Inc. and Westaim Arena Holdings II LLC since 2016. His previous roles include Chairman of the Management ...

Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has dipped another ... is an inhibitor of the angiotensin II type 2 receptor (AT2R) and thought ...

Steven Paul Executive Vice President, Science and Technology and President, Lilly Research Laboratories (LRL), Eli Lilly and Company ... preferably before Phase II, using surrogate end points ...